Immunicon (NASDAQ:IMMC)
Historical Stock Chart
From Sep 2019 to Sep 2024
Immunicon Corporation (NASDAQ-CM:IMMC) announced today that, effective
as of today’s date, its common stock began
quotation on the Over-the-Counter Bulletin Board. As disclosed
previously, Immunicon had received notification from The NASDAQ Stock
Market indicating that trading in Immunicon’s
common stock would be suspended and Immunicon’s
common stock would be delisted from The NASDAQ Capital Market at the
opening of business on April 29, 2008, unless Immunicon appealed NASDAQ’s
determination. In response, on April 18, 2008, Immunicon notified NASDAQ
that it would not submit such a plan but rather would pursue quotation
of its common stock on the Over-the-Counter Bulletin Board.
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary
cell- and molecular-based human diagnostic and life science research
products, and is providing certain analytical services to pharmaceutical
and biotechnology companies to assist them in developing new therapeutic
agents, with an initial focus on cancer disease management. Immunicon
has developed platform technologies to identify, count and characterize
a small number of rare cells in blood, such as circulating tumor cells
and circulating endothelial cells that are important in many diseases
and biological processes. Immunicon’s products
and underlying technology platforms also have application in cancer
research and may have applications in other fields of medicine, such as
cardiovascular and infectious diseases. For more information, please
visit www.immunicon.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are often preceded by words such as “hope,”
“may,” “believe,”
“anticipate,” “plan,”
“expect,” “intend,”
“assume,” “will”
and similar expressions. Forward-looking statements contained in this
press release are those statements not of historical fact. Immunicon
cautions investors not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release, are
based on the current expectations and intent of the management of
Immunicon and involve certain factors, such as risks and uncertainties
that may cause actual results to be far different from those suggested
by these statements. These statements are not guarantees of future
performance and involve risks and uncertainties that are difficult to
predict, including, but not limited to, risks and uncertainties
associated with: Immunicon’s ability to
continue as a going concern; Immunicon’s
dependence on Veridex, LLC, a Johnson & Johnson company; the risks and
uncertainties associated with the arbitration proceeding with Veridex
and the award in favor of Veridex given Immunicon’s
dependence on Veridex; the ability to earn license and milestone
payments under Immunicon’s agreement with
Veridex; Immunicon’s capital and financing
needs; research and development and clinical trial expenditures;
commercialization of product candidates; Immunicon’s
ability to obtain licenses from third parties to commercialize products;
Immunicon’s ability to manage its growth;
obtaining necessary regulatory approvals; reliance on third party
manufacturers and suppliers; reimbursement by third party payors to
Immunicon’s customers; compliance with
applicable manufacturing standards; retaining key personnel; delays in
the development of new products or planned improvements to products;
effectiveness of products compared to competitors’
products; protection of Immunicon’s
intellectual property; conflicts with third party intellectual property;
product liability lawsuits that may be brought against Immunicon; labor,
contract or technical difficulties; and competitive pressures in
Immunicon’s industry. These factors are
discussed in more detail in Immunicon’s
filings with the Securities and Exchange Commission. Except as required
by law, Immunicon accepts no responsibility for updating the information
contained in this press release beyond the published date, whether as a
result of new information, future events or otherwise, or for
modifications made to this document by Internet or wire services.
“Immunicon” and
the Immunicon Corporation logo are registered trademarks of Immunicon
Corporation. ALL RIGHTS RESERVED.